Immunotherapy
Assess therapeutic response through PD-LI testing
Immunotherapies have recently emerged as a therapeutic option for patients with non-small cell lung cancer (NSCLC). Therapies have been approved for both first- and second-line treatments of NSCLC tumors with specific patterns of PD-L1 expression.
Immunotherapy test menu
Immunotherapy
Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific therapies. The specific PD-L1 clone, scoring method, and eligibility requirements depend on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor under consideration.
The FDA List of Cleared or Approved Companion Diagnostic Devices is frequently updated and provides current guidance for treatment indications and scoring.
Key testing
- 22C3 | Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual
- 288PD | Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual
- SP263 | Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual
- SP142 | Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual